Nasdaq · Healthcare

Sarepta Therapeutics, Inc. (SRPT)

As-reported financials and recent SEC filings for Sarepta Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$1.86B

Net income

$-713.4M

Net margin

-38.3%

Diluted EPS

$-7.13

ROE

-62.5%

P/E (TTM)

48.1×

Market cap

$1.78B

Debt / equity

0.7×

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$1.86B	$1.79B	$1.14B	$843.8M	$612.4M
Gross profit	—	—	—	—	—
Operating income	$-699.8M	$218.1M	$-267.8M	$-536.2M	$-459.7M
Net income	$-713.4M	$235.2M	$-536.0M	$-703.5M	$-418.8M
Diluted EPS	$-7.13	$2.34	$-5.80	$-8.03	$-5.15

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

42026-06-05

42026-06-05

42026-06-05

42026-06-05

42026-06-05

42026-06-05

42026-06-05

42026-06-05

Go deeper on SRPT

Search Sarepta Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.